Induction Chemotherapy Followed by Radiation Therapy Versus Surgery Followed by Concurrent Chemo-Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Oral Cavity.
concurrent chemo-radiation
induction chemotherapy
oral cavity cancer
radiation therapy
tpf chemotherapy
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
accepted:
17
06
2021
entrez:
22
7
2021
pubmed:
23
7
2021
medline:
23
7
2021
Statut:
epublish
Résumé
Introduction Squamous cell carcinoma of the oral cavity is one of the top 10 malignancies reported globally. Pakistan has a high incidence of oral cancers due to the prevailing poor lifestyle habits/addictions of Pakistanis, and most patients with squamous cell carcinoma present with stage III or IV locally advanced disease. Recommended guidelines indicate surgery as the mainstay of treatment followed by radiotherapy (RT). The addition of induction chemotherapy before surgery or radiation therapy might improve outcomes with increased locoregional control rates. Methods This was a retrospective cohort study comparing the outcomes between surgery followed by concurrent chemoradiotherapy (CCRT) and induction chemotherapy followed by RT. This study primarily aimed to evaluate progression-free survival (PFS) and determine the toxicity of chemotherapy. Results We found out that the mean PFS among patients undergoing surgery and CCRT and those receiving induction chemotherapy followed by RT were 6.40 (± 2.38) months and 7.6 (± 4.76) months, respectively. Conclusion Induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by RT shows satisfactory results with acceptable toxicity. However, the results are not statistically significant but support the already published data on this treatment aspect of oral cavity cancers.
Identifiants
pubmed: 34290920
doi: 10.7759/cureus.15723
pmc: PMC8287840
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e15723Informations de copyright
Copyright © 2021, Hussain A. Ali et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Cancer. 2000 Apr 1;86(1):128-31
pubmed: 10728606
Asian Pac J Cancer Prev. 2005 Jan-Mar;6(1):22-6
pubmed: 15780026
Gulf J Oncolog. 2020 Jan;1(32):12-28
pubmed: 32342913
Cancer Sci. 2011 Feb;102(2):460-7
pubmed: 21129124
J Patient Rep Outcomes. 2017;2(1):2
pubmed: 29757309
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Ayub Med Coll Abbottabad. 2005 Jan-Mar;17(1):65-6
pubmed: 15929532
Oral Oncol. 2009 Apr-May;45(4-5):454-60
pubmed: 18804412
J Pak Med Assoc. 2006 Mar;56(3):124-30
pubmed: 16696512
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Asia Pac J Public Health. 2011 Nov;23(6):1021-4
pubmed: 22144715
Lancet Oncol. 2013 Mar;14(3):257-64
pubmed: 23414589
Ann Oncol. 2017 Sep 1;28(9):2206-2212
pubmed: 28911070
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Lancet Oncol. 2011 Feb;12(2):153-9
pubmed: 21233014
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Oncologist. 2010;15 Suppl 3:3-7
pubmed: 21036882
J Pak Med Assoc. 1987 Jul;37(7):178-83
pubmed: 3118073
East Mediterr Health J. 2010;16 Suppl:S24-30
pubmed: 21495585
PLoS One. 2011;6(10):e25347
pubmed: 22039411
Oral Oncol. 2006 Aug;42(7):675-84
pubmed: 16731029